Therefore, an expression analysis of ST14/Prss14, for example by classical immunohistochemical analysis as performed in earlier reports [48, 49], together with those of ER and HER2 would provide an added benefit to predict the prognosis of breast cancer patients. Here, ERBB2 is linked to breast carcinoma.